The Hypotensor's Function for PKD

Researches have proven that if Polycystic Kidney Disease (PKD) patients take effective hypotenor and control their blood pressure well, it will postpone the occurrence of uremia for about 15 years.

Most PKD patients are belong to ADPKD (autosomal dominant inheritance PKD. Patients' kidneys are full of various cysts and with the enlargement of them they will cause serious complications and even renal failure. 70 percent of patients have the symptom of hypertension and hypertension usually will cause renal failure and cardiovascular disease, and this is one of the common cause of death of PKD patients.

Chairman Schrier, the chairman of medical department of Colorado State University in America, has proven that if PKD patients control the blood pressure well at the very early stage, it at least will make the first 15 years of patients away from dialysis. Chairman Schrier and his colleagues divide 24 PKD patients with hypertension into two groups and give them Amlodipine ( a kind of calcium antagonist) and Enalapril ( a kind of angiotensin converting enzyme) separately. Then take the track record for 5 years. When the research finished, all the patients' blood pressure is on the level of 120/80 and their renal function is better than that of patients who take no hypotensor medicine, and the proteinuria of patients who took Enalapril has declined obviously. Urine protein is the most common index of reflecting the development of kidney disease. Therefore, Enalapril may be the best hypotensor to control the blood pressure for PKD patients.

All over the world, there are 12-15 million children have this disease, and in America, there are 10 percent of renal failure is caused by PKD and these patients usually have to take dialysis for treatment. By controlling blood pressure to postpone the dialysis means improving the life quality of patients.

However, patients should not forget that hypertension is only a symptom of PKD. Controlling the blood pressure is not the fundamental method. The fundamental therapy should aim at contracting the cysts of PKD and protecting renal function. Preventing the attack of PKD is the key point. As for the treatment of PKD. A brand new method to treat PKD, Micro-Chinese Medicine Osmotherapy, combines traditional Chinese medicine with Western medicine. It makes new breakthroughs on both treatment method and medical methods. Its medical method, differing from traditional Chinese medicine, Micro-Chinese Medicine Osmotherapy permeates the medicine directly to kidney by external permeation and its medicine utilization is rather high. The medicine permeated into kidney can effectively relieve the condition of ischemia and anoxia, accelerate the the resorption of cysts liquid, restrain the secretion of cyst liquid and at last achieve the goals of contracting cysts and preventing its recurring. Meanwhile Micro-Chinese Medicine cooperates with Western medicine in order to block the inflammation, which can make a good environment for the effects of Chinese medicine. Micro-Chinese Medicine Osmotherapy brings no harm to patients and the disease seldom recurs. If you have other questions about PKD or its treatment, please contact us on-line or by email: kidney-treatment@hotmail.com.